134 related articles for article (PubMed ID: 25550599)
1. Inhibition of placental growth factor in renal cell carcinoma.
Bessho H; Wong B; Huang D; Siew EY; Huang D; Tan J; Ong CK; Tan SY; Matsumoto K; Iwamura M; Teh BT
Anticancer Res; 2015 Jan; 35(1):531-41. PubMed ID: 25550599
[TBL] [Abstract][Full Text] [Related]
2. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
Huang D; Ding Y; Li Y; Luo WM; Zhang ZF; Snider J; Vandenbeldt K; Qian CN; Teh BT
Cancer Res; 2010 Feb; 70(3):1053-62. PubMed ID: 20103629
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
[TBL] [Abstract][Full Text] [Related]
4. EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming.
Adelaiye-Ogala R; Budka J; Damayanti NP; Arrington J; Ferris M; Hsu CC; Chintala S; Orillion A; Miles KM; Shen L; Elbanna M; Ciamporcero E; Arisa S; Pettazzoni P; Draetta GF; Seshadri M; Hancock B; Radovich M; Kota J; Buck M; Keilhack H; McCarthy BP; Persohn SA; Territo PR; Zang Y; Irudayaraj J; Tao WA; Hollenhorst P; Pili R
Cancer Res; 2017 Dec; 77(23):6651-6666. PubMed ID: 28978636
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Sphingosine Phosphate Receptor 1 Signaling Enhances the Efficacy of VEGF Receptor Inhibition.
Fischl AS; Wang X; Falcon BL; Almonte-Baldonado R; Bodenmiller D; Evans G; Stewart J; Wilson T; Hipskind P; Manro J; Uhlik MT; Chintharlapalli S; Gerald D; Alsop DC; Benjamin LE; Bhatt RS
Mol Cancer Ther; 2019 Apr; 18(4):856-867. PubMed ID: 30787172
[TBL] [Abstract][Full Text] [Related]
6. Pleiotropic stromal effects of vascular endothelial growth factor receptor 2 antibody therapy in renal cell carcinoma models.
Duignan IJ; Corcoran E; Pennello A; Plym MJ; Amatulli M; Claros N; Iacolina M; Youssoufian H; Witte L; Samakoglu S; Schwartz J; Surguladze D; Tonra JR
Neoplasia; 2011 Jan; 13(1):49-59. PubMed ID: 21245940
[TBL] [Abstract][Full Text] [Related]
7. Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts.
Miles KM; Seshadri M; Ciamporcero E; Adelaiye R; Gillard B; Sotomayor P; Attwood K; Shen L; Conroy D; Kuhnert F; Lalani AS; Thurston G; Pili R
PLoS One; 2014; 9(11):e112371. PubMed ID: 25393540
[TBL] [Abstract][Full Text] [Related]
8. Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.
Shibasaki N; Yamasaki T; Kanno T; Arakaki R; Sakamoto H; Utsunomiya N; Inoue T; Tsuruyama T; Nakamura E; Ogawa O; Kamba T
PLoS One; 2015; 10(6):e0130980. PubMed ID: 26114873
[TBL] [Abstract][Full Text] [Related]
9. Placental growth factor (PlGF)-specific uptake in tumor microenvironment of 89Zr-labeled PlGF antibody RO5323441.
Oude Munnink TH; Tamas KR; Lub-de Hooge MN; Vedelaar SR; Timmer-Bosscha H; Walenkamp AM; Weidner KM; Herting F; Tessier J; de Vries EG
J Nucl Med; 2013 Jun; 54(6):929-35. PubMed ID: 23625582
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma.
Huang D; Ding Y; Zhou M; Rini BI; Petillo D; Qian CN; Kahnoski R; Futreal PA; Furge KA; Teh BT
Cancer Res; 2010 Feb; 70(3):1063-71. PubMed ID: 20103651
[TBL] [Abstract][Full Text] [Related]
11. Cellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma.
Han KS; Raven PA; Frees S; Gust K; Fazli L; Ettinger S; Hong SJ; Kollmannsberger C; Gleave ME; So AI
Neoplasia; 2015 Nov; 17(11):805-16. PubMed ID: 26678908
[TBL] [Abstract][Full Text] [Related]
12. Dynamic contrast-enhanced magnetic resonance imaging of vascular changes induced by sunitinib in papillary renal cell carcinoma xenograft tumors.
Hillman GG; Singh-Gupta V; Zhang H; Al-Bashir AK; Katkuri Y; Li M; Yunker CK; Patel AD; Abrams J; Haacke EM
Neoplasia; 2009 Sep; 11(9):910-20. PubMed ID: 19724685
[TBL] [Abstract][Full Text] [Related]
13. Autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma.
Su SC; Hu X; Kenney PA; Merrill MM; Babaian KN; Zhang XY; Maity T; Yang SF; Lin X; Wood CG
Clin Cancer Res; 2013 Dec; 19(23):6461-72. PubMed ID: 24122794
[TBL] [Abstract][Full Text] [Related]
14. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study.
Hammers HJ; Verheul HM; Salumbides B; Sharma R; Rudek M; Jaspers J; Shah P; Ellis L; Shen L; Paesante S; Dykema K; Furge K; Teh BT; Netto G; Pili R
Mol Cancer Ther; 2010 Jun; 9(6):1525-35. PubMed ID: 20501804
[TBL] [Abstract][Full Text] [Related]
15. NGAL can alternately mediate sunitinib resistance in renal cell carcinoma.
Yu DS; Wu CL; Ping SY; Huang YL; Shen KH
J Urol; 2014 Aug; 192(2):559-66. PubMed ID: 24423438
[TBL] [Abstract][Full Text] [Related]
16. Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib.
Serova M; Tijeras-Raballand A; Dos Santos C; Martinet M; Neuzillet C; Lopez A; Mitchell DC; Bryan BA; Gapihan G; Janin A; Bousquet G; Riveiro ME; Bieche I; Faivre S; Raymond E; de Gramont A
Oncotarget; 2016 Jun; 7(25):38467-86. PubMed ID: 27509260
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions.
Rini BI
Clin Cancer Res; 2007 Feb; 13(4):1098-106. PubMed ID: 17317817
[TBL] [Abstract][Full Text] [Related]
18. Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis.
Jeong DE; Song HJ; Lim S; Lee SJ; Lim JE; Nam DH; Joo KM; Jeong BC; Jeon SS; Choi HY; Lee HW
Oncotarget; 2015 Oct; 6(32):33046-64. PubMed ID: 26426994
[TBL] [Abstract][Full Text] [Related]
19. Human choriocarcinomas: placental growth factor-dependent preclinical tumor models.
Bagley RG; Ren Y; Kurtzberg L; Weber W; Bangari D; Brondyk W; Teicher BA
Int J Oncol; 2012 Feb; 40(2):479-86. PubMed ID: 22075622
[TBL] [Abstract][Full Text] [Related]
20. Antiangiogenic chemotherapeutic agents: characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models.
Schirner M; Hoffmann J; Menrad A; Schneider MR
Clin Cancer Res; 1998 May; 4(5):1331-6. PubMed ID: 9607594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
